Thrivent Financial For Lutherans Reata Pharmaceuticals Inc Transaction History

Thrivent Financial For Lutherans

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 17, 2023	SELL	$30.85 - $93.17 $2.05 Million - $6.2 Million	-66,555 Reduced 90.71%	6,819 $620,000
Q4 2022 Feb 08, 2023	BUY	$22.15 - $42.11 $800,855 - $1.52 Million	36,156 Added 97.15%	73,374 $2.79 Million
Q3 2022 Nov 14, 2022	BUY	$19.41 - $36.49 $722,401 - $1.36 Million	37,218 New	37,218 $935,000
Q4 2021 Feb 16, 2022	SELL	$25.61 - $110.96 $1 Million - $4.34 Million	-39,135 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$100.0 - $143.02 $7,500 - $10,726	-75 Reduced 0.19%	39,135 $3.94 Million
Q2 2021 Aug 19, 2021	SELL	$78.27 - $151.29 $955,754 - $1.85 Million	-12,211 Reduced 23.75%	39,210 $5.55 Million
Q1 2021 May 17, 2021	SELL	$94.25 - $132.81 $206,596 - $291,119	-2,192 Reduced 4.09%	51,421 $5.13 Million
Q4 2020 Feb 16, 2021	BUY	$102.03 - $184.62 $4.06 Million - $7.35 Million	39,824 Added 288.81%	53,613 $6.63 Million
Q3 2020 Nov 10, 2020	SELL	$93.53 - $163.34 $76,507 - $133,612	-818 Reduced 5.6%	13,789 $1.34 Million
Q1 2020 May 15, 2020	BUY	$124.16 - $247.74 $1.81 Million - $3.62 Million	14,607 New	14,607 $2.11 Million

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

Stay updated on Thrivent Financial For Lutherans with notifications on news.